Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 versus placebo in moderate to severe COPD
NL-OMON34669Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing NVA237 with Placebo (2 arms). Primary endpoint: Trough FEV1 at Week 12. Started Mar 2010; status: active, not recruiting.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON34669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34669.